Revolution Medicines (RVMDW) Receivables - Other (2019 - 2020)
Revolution Medicines (RVMDW) posted quarterly Receivables - Other of $6.4 million for Q4 2020, down 26.83% year-over-year from $8.7 million in Q1 2020, and down 31.25% quarter-over-quarter from $9.3 million in Q3 2020.
Revolution Medicines (RVMDW) Receivables - Other (2019 - 2020) Analysis & Trends
Revolution Medicines' Receivables - Other history runs 2 years deep, the most recent figure standing at $6.4 million for Q4 2020.
- In Q4 2020, Receivables - Other fell 26.83% year-over-year to $6.4 million; the TTM figure through Dec 2020 stood at $6.4 million (down 26.83% YoY), while the FY2020 annual figure was $6.4 million, down 26.83% from the prior year.
- Receivables - Other for Q4 2020 stood at $6.4 million, down from $9.3 million in the prior quarter.
- The five-year high for Receivables - Other was $9.3 million in Q3 2020, with the low at $6.4 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Revolution Medicines | 2.45 Bn | 2.45 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 6.39 Mn |
| Dec 31, 2020 | 6.39 Mn |
| Sep 30, 2020 | 9.30 Mn |
| Sep 30, 2020 | 9.30 Mn |
| Jun 30, 2020 | 7.33 Mn |
| Jun 30, 2020 | 7.33 Mn |
| Mar 31, 2020 | 8.45 Mn |
| Mar 31, 2020 | 8.45 Mn |
| Dec 31, 2019 | 8.74 Mn |
| Dec 31, 2019 | 8.74 Mn |